

1 **Prolonged Water-only Fasting is a Safe and Feasible Treatment Option for Managing**
2 **Stage 1 and 2 Hypertension**

3
4 **Evelyn Zeiler¹, Sahmla Gabriel¹, Mackson Ncube¹, Natasha Thompson¹, Eugene Scharf²,**
5 **Alan C. Goldhamer³, Toshia R. Myers^{1*}**

6 1. TrueNorth Health Foundation, Santa Rosa, CA, USA

7 2. Department of Neurology, Mayo Clinic Rochester, MN, USA

8 3. TrueNorth Health Center, Santa Rosa, California, USA

9 ***Correspondence**

10 Toshia Myers

11 drmyers@truenorthhealth.org

12

13

14 **Word count:** 4607

15

16 **Keywords:** hypertension, prolonged water-only fasting, prolonged fasting, adverse events,
17 whole-plant-food diet, anti-hypertensive medication use

18

19

20

21

22

23

24

25

26 **Abstract**

27 Prolonged water-only fasting appears to reduce high blood pressure but randomized controlled
28 trials are needed. This single arm pre-post interventional trial (clinicaltrials.gov, NCT04515095)
29 investigates the safety, feasibility, and effectiveness of prolonged water-only fasting in the
30 treatment of stage 1 and 2 hypertension. Twenty-nine participants with stage 1 and 2
31 hypertension, who were pre-approved to water-only fast for ≥ 7 days, were enrolled from a
32 residential fasting center. Participants received 24-hour medical supervision, and adverse events
33 were recorded according to Common Terminology Criteria for Adverse Events (CTCAE)
34 version 5.0. Feasibility was assessed based on retention rate, ability to complete minimal fast
35 length, and intervention acceptability. Demographic, anthropometric, medication use, laboratory,
36 and survey data were also collected. Twenty-seven of the 29 enrolled participants attended all
37 study visits through the six-week follow-up visit and completed at least seven consecutive days
38 of water-only fasting. The majority of adverse events were mild and transient and there were no
39 higher-grade or serious adverse events. Overall, the intervention was acceptable. At the six-week
40 follow-up visit, there were sustained reductions in median systolic/diastolic blood pressure (-
41 19.19/-5.13 mmHg), body weight (-6.72 kg), abdominal circumference -6.55 cm), and anti-
42 hypertensive medication use (-93%), which also persisted at the 12-month follow-up visit. These
43 preliminary data suggest that prolonged water-only fasting is a safe and feasible treatment option
44 for stage 1 and 2 hypertension. The data also suggest that fasting may result in sustainable
45 reductions in high blood pressure and anti-hypertensive medication use.

46

47

48

49

50

51

52

53

54

55

56

57 **1 Introduction**

58 Hypertension (HTN) affects nearly half of US American adults[1; 2; 3] and associated healthcare
59 costs are estimated at 131 billion USD annually.[4] Uncontrolled HTN is a modifiable risk factor
60 for developing ischemic heart disease, stroke, and other types of cardiovascular disease (CVD)
61 as well as renal disease.[2; 3] The risk of developing CVD due to high blood pressure (BP)
62 reportedly doubles with every 20/10 mmHg increase in systolic blood pressure (SBP)/DBP
63 above 115/75 mmHg.[5] Current treatment guidelines recommend that all patients with high BP
64 implement diet and lifestyle modifications and for anti-hypertensive medications to be prescribed
65 in high-risk patients with SBP/DBP \geq 130/80 mmHg (Stage 1) or \geq 140/90 mmHg (Stage 2).[5] It
66 has been reported that as many as 60% of medicated HTN patients continue to have uncontrolled
67 high BP and that anti-hypertensive medications result in modest BP reductions and/or have low
68 rates of adherence, potentially due to adverse side effects.[6; 7] Furthermore, anti-hypertensive
69 medications only confer significant risk reduction in patients already at high risk for developing
70 CVD. [8]

71 Although diet and lifestyle modifications may lower high BP as well as associated CVD risks
72 and rates of polypharmacy, these interventions have proven challenging to implement and also
73 have low adherence rates.[9; 10; 11] Preliminary research suggests that medically supervised,
74 prolonged water-only fasting followed by an exclusively whole-plant-food diet free of added
75 salt, oil, and sugar (SOS-Free Diet) has a very low risk of causing a severe or serious adverse
76 event, results in immediate and sustained improvements in blood pressure and other biomarkers
77 of CVD risk, and may improve adherence to diet and lifestyle modifications.[12; 13; 14; 15; 16]
78 In order to continue evaluating if the intervention has potential as a HTN treatment, we
79 conducted a single-arm pre-post interventional trial with the primary aim of assessing safety and
80 feasibility in people with stage 1 and 2 hypertension by systematically collecting and reporting
81 adverse events and treatment deviations as well as study retention rate, ability to complete
82 minimal fast length, and self-reported intervention acceptability. Additionally, we measured the
83 immediate, sustained, and long-term effects of the full intervention on BP and other
84 cardiometabolic risk factors.

85

86 **2 Methods**

87 **Ethical Approval**

88 This study was approved by the TrueNorth Health Foundation Institutional Review Board
89 (TNHF2020-1HTN and TNHF2021-1HTNFU) and registered at clinicaltrials.gov
90 (NCT04515095). The research was conducted in accordance with the approved protocol and
91 complied with the standards of the Declaration of Helsinki. All participants provided written
92 informed consent before data collection began.

93 **Participant Enrollment and Study Protocol**

94 This study was a single-arm pre-post intervention trial that recruited patients with stage 1 and 2
95 hypertension who were undergoing an elective, medically supervised, water-only fast of at least
96 seven days at a residential fasting center between August 2020 and September 2021. Thirty

97 participants were enrolled, of which one was ineligible due to preexisting hyponatremia that
98 contraindicates fasting (**Figure 1, ST1**). Consenting participants of any sex, aged 30-75 years,
99 with uncontrolled (SBP \geq 130 mmHg and/or DBP \geq 80 mmHg) or medication-controlled
100 hypertension, fasting glucose $<$ 126 mg/dL and/or hemoglobin A1c $<$ 7%, and prior approval by a
101 non-research physician to water-only fast for at least seven consecutive days followed by a
102 refeeding period of at least half the fasting length, were eligible for inclusion. Exclusion criteria
103 included SBP $>$ 180 and/or DBP $>$ 120 mmHg at time of enrollment, active malignancy, active
104 kidney disease, active inflammatory disorder (including classic autoimmune connective tissue
105 disorders, multiple sclerosis, inflammatory bowel disorders), stroke or heart attack within the last
106 90 days, and the inability to discontinue medications and/or supplements. Study dates overlapped
107 with NCT04514146, conducted at the same fasting center, and 18/29 participants were co-
108 enrolled in that study.[15]

109 Demographic information, medical diagnoses, and current use of anti-hypertensive medications
110 were collected at BL, 6wFU, and 12mFU visits (see below). During the treatment period, onsite
111 study visits occurred daily and at baseline (BL), end of fast (EOF), and end of refeed (EOR).
112 Two additional study visits occurred either onsite or remotely: an expected visit that occurred six
113 weeks after departure from the fasting center (6wFU) and an unexpected visit that occurred 12
114 months after the 6wFU visit (12mFU). During daily visits, body weight (BW), BP, peripheral
115 oxygen saturation (SpO₂), body temperature (BT), and pulse were measured and adverse events
116 (AEs) were recorded. Additionally, BW, BP, abdominal circumference (AC), and blood and
117 urine samples were collected at BL, EOF, EOR, 6wFU, and 12mFU visits (see below). Web-
118 based versions of three questionnaires were administered: the SOS-Free Diet Screener[15] at BL,
119 6wFU, and 12mFU visits; the Treatment Adherence/Acceptability Scale (TAAS)[17]
120 questionnaire at EOF and 6wFU visits; and the Food Acceptability Questionnaire (FAQ)[18] at
121 BL, EOR, 6wFU, and 12mFU visits. Details about the questionnaires can be found in the
122 supplemental material. Demographic information, medical diagnoses, and current use of anti-
123 hypertensive medications were collected at BL, 6wFU, and 12mFU visits (see Supplemental
124 Material). Data collection and survey distribution were performed using the web-based software
125 Research Electronic Data Capture (REDCap).[19] Missing data are described in **ST1** and in the
126 legend of respective tables.

127 **Medically Supervised, Water-only Fasting Protocol**

128 The prefeeding, water-only fasting, and refeeding protocol took place at a residential fasting
129 center. The protocol was previously described in detail [14]. Participants were approved to
130 water-only fast by medical doctors not affiliated with this study after a thorough examination,
131 which included detailed patient history, comprehensive physical exam, basic neurological and
132 psychological status, complete blood count (CBC), comprehensive metabolic panel (CMP),
133 urinalysis, and additional tests as clinically indicated. Medication use while water-only fasting is
134 contraindicated and ability to discontinue medication use safely was a requirement for
135 enrollment in this study. Participants received 24-hour medical supervision during the entire
136 treatment (i.e., prefeeding, water-only fasting, and refeeding). Vital signs were examined by
137 medical personnel twice per day and labs were ordered once per week or as requested by the
138 attending physician.

139 *Prefeeding*

140 A prefeeding period began at least two days prior to the water-only fast, during which
141 participants eliminated all recreational drugs (e.g., coffee, alcohol, nicotine, etc.) and specific
142 foods (i.e., grains, legumes, dairy, meat, seafood, added sugar, oils and salt, and all processed
143 foods) and ate only the provided raw/steamed fruits and vegetables. During this time,
144 participants were weaned off anti-hypertensive and other medications as determined appropriate
145 by the attending physician based on clinical protocol and according to the individual
146 participant's medical needs.

147 *Fasting*

148 During the water-only fast, participants drank a minimum of 1.2 L/day of steam-distilled water.
149 If medically indicated (e.g., due to blood electrolyte imbalance, hypoglycemia, or
150 gastroesophageal reflux disease) or desired by the participant, vegetable broth (VB; 80 kcal per
151 day) was consumed. VB has such an insignificant amount of calories that it does not prevent
152 ketosis or reverse ketosis once it has been initiated and is assumed equivalent to water. The fast
153 continued for the predetermined amount of time or modified according to the individual patient's
154 needs. In cases of more severe adverse events or discomfort, the fast was temporarily or
155 indefinitely broken with fruit and vegetable juice (500-600 kcal per day) or potato/zucchini blend
156 (900 kcal per day).

157 *Refeeding*

158 The refeeding diet was administered in five phases: 1) fruit and vegetable juice; 2) raw
159 fruits/vegetables; 3) raw/steamed vegetables and fruits; 4) raw/steamed fruits and vegetables,
160 grains, and nuts or avocado; 5) unrestricted whole-plant foods free of added salt, oil, and sugar.
161 Each of the five refeeding phases lasted one day for every 7-10 days of water-only fasting, for a
162 period of time lasting at least one half of the total fast length (e.g., 10 days of fasting would
163 correspond to five days of refeeding with one day on each of the five phases). If medically
164 indicated (e.g., due to food intolerance), the refeeding protocol was modified.[14] Before leaving
165 the center, participants received basic nutrition education and were instructed to continue the
166 exclusively whole-plant-food, SOS-free diet for at least the next six weeks. There were no
167 further instructions after the 6wFU visit.

168 **Adverse Events Recording & Analysis**

169 While prefeeding, fasting and refeeding, AEs were identified in daily interviews conducted by
170 trained clinical research personnel, daily physical (i.e., daily vitals) examinations, weekly blood
171 analysis (i.e., CBC and CMP), and weekly urinalysis. AEs were recorded by date and according
172 to Common Terminology Criteria for Adverse Events (CTCAE)[20] based on symptom
173 categorization and severity (grade 1, mild; grade 2, moderate; grade 3, severe; grade 4, life-
174 threatening; grade 5, death). The CTCAE describes AE terms according to the Medical
175 Dictionary for Regulatory Activities (MedDRA), as lowest-level terms (LLT) that are grouped
176 into a system organ class (SOC). For terms not specifically listed in the CTCAE and listed under
177 the MedDRA SOC as 'other', new terms were added and graded according to the CTCAE
178 guideline that described the AE as best as possible. All AEs were reported regardless of
179 attribution. Pre-existing conditions were considered an AE if reoccurring or increasing in
180 severity at any time during the intervention. The same AE may have occurred multiple times for

181 the same participant and was counted as a new event if it decreased or increased in grade or had
182 previously resolved but subsequently returned. AE outcomes (i.e., resolved, persisted, unknown)
183 were determined as follows: the outcome was considered “resolved” if the symptom cleared
184 completely or the severity of the event decreased (e.g., G2 decreased to G1). The outcome was
185 considered “persisted” if the AE did not resolve at EOR or 6wFU visit. The outcome was
186 considered "unknown" if the interview or specific analysis was not repeated (only AEs
187 determined by CMP and CBC were monitored at 6wFU) or if the participant failed to report back
188 at the 6wFU visit. The total number of AEs for all participants during the entire intervention was
189 counted and presented based on SOC, LLT, grade, and outcome. Additionally, the top 10% of
190 total AEs experienced by participants were presented based on LLT, grade, and treatment phase
191 (i.e., prefeeding, fasting, and refeeding). AEs were further categorized as the highest-grade
192 adverse event (HGAE) during the entirety of each participant’s intervention.

193 **Demographics, Medical Diagnoses, Medication Use, and Anthropometric Measurements**

194 Demographic information (age, sex), current and past medical diagnoses, and current medication
195 use was collected by interview at BL and self-reported at 6wFU and 12mFU visits using an
196 online survey. Height (cm) was measured once at BL with a digital wall mounted stadiometer
197 (DS5100, Doran Scales Inc., St. Charles, IL, USA) and used to calculate body mass index (BMI)
198 at each time point. Participants were instructed to wear only one layer of clothing and remove
199 shoes and any pocket items for BW measurements. BW (kg) was measured using a digital body
200 scale (BWB 800A Class III, Tanita Corporation of American Inc., Arlington Heights, IL, USA)
201 while onsite and with the provided digital floor scale (WW26, Conair LLC, Stamford, CT, USA)
202 while offsite. AC (cm) was measured horizontally on a bare abdomen at the minimal waistline
203 and parallel to the floor with a tension-sensitive, non-elastic tape (Gullick II, Model 67019,
204 Country Technology Inc., Gay Mills, WI, USA) while onsite or with the provided retractable
205 tape measure while offsite. The measurement was read in the midaxillary line and at the end of a
206 normal expiration. BP was measured while the participant was resting in a seated position and
207 their left arm elevated to heart level. A digital blood pressure device (Welch Allyn-Connex
208 ProBP 3400, Hill-Rom Holding Inc. Chicago, IL, USA) was used while onsite and a blood
209 pressure monitor (BP3GX1, Microlife USA Inc, Clearwater, FL, USA) for the offsite visits.
210 Participants received thorough education as well as written instructions in order to provide self-
211 reported measurements at 6wFU and 12mFU visits.

212 **Biospecimen Collection**

213 For onsite visits, serum and plasma blood samples as well as 24-hour urine were collected and
214 sent to LabCorp (LabCorp, Burlington, NC, USA). For offsite visits, the samples were collected
215 directly at a LabCorp local to the participant. All blood samples were drawn by a certified
216 phlebotomist. Blood samples were drawn while onsite by a certified phlebotomist at BL, EOF,
217 and EOR and at a local LabCorp for the off-site 6wFU and 12mFU visits. Blood collection took
218 place in the morning, before the consumption of caloric food or liquid but with the instruction to
219 consume 1-2 cups of water prior to arrival. While in a seated position, blood was collected into
220 one red top (Red top, 16 × 100, 10 mL, silica, BD, Mississauga, ON, Canada) and one lavender
221 top vacutainer tube (Lavender top, 13x75, 4.0 ml, K2EDTA, BD, Mississauga, ON, Canada).
222 The lavender top vacutainer was placed into an ice/water bath immediately after collection and
223 stored at 4°C until it was sent to a commercial laboratory (LabCorp, Burlington, NC, USA) for

224 complete blood count (CBC) analysis. LabCorp reports that CBC analysis was completed using
225 an Auto cell counter with mixed technologies from Sysmex (Sysmex Asia Pacific Pte Ltd, Asia
226 Green, Singapore). The red top vacutainer tube was incubated at room temperature for 30-50 min
227 and centrifuged at 1500g for 10 minutes at 4°C (Model: Thermo Scientific Sorvall Legend X1R,
228 Rotor: TX-400 Rotor Cross, Thermo Fisher Scientific Inc., Waltham, MA, USA). The serum was
229 separated and stored at 4°C until it was sent to LabCorp for comprehensive metabolic panel
230 (CMP) analysis, lipid panel (total cholesterol, HDL-, LDL-, VLDL-cholesterol, triglycerides), C-
231 reactive protein (CRP), gamma-glutamyl transferase (GGT), and insulin. LabCorp reports that
232 CMP was measured using Ion Selective Electrode (ISE), colorimetric, enzymatic, and kinetic
233 methods from Roche Diagnostics (Roche Diagnostics, Indianapolis, IN, USA), lipid panel by
234 colorimetric and enzymatic methods, insulin by electrochemiluminescence immunoassays
235 (ECLIA), CRP by high sensitivity immunochemiluminometric assays (ICMA), and GGT by
236 kinetic methods from Roche Diagnostics (Roche Diagnostics, Indianapolis, IN, USA).

237 Participants collected 24-hour urine samples at BL, EOF, EOR, 6wFU, and 12mFU visits. The
238 collection started after the first void was discarded and subsequent voids were collected into one
239 or two additive-free urine containers (LabCorp) and stored at 4°C for the next 24 hours. After
240 completion, 24-hour urine samples were combined and/or inverted to ensure homogeneity and
241 the total volume was assessed. 50 ml was transferred into a cup and a dipstick urinalysis
242 (Siemens Multistix 10SG [Siemens Medical Solutions USA, Inc., Malvern, PA, USA] or
243 Mission Urinalysis Strips [ACON Laboratories, Inc., San Diego, CA, USA]) was performed at
244 BL, EOF, and EOR to measure leukocytes, nitrite, urobilinogen, protein, pH, blood, specific
245 gravity, ketone, bilirubin, and glucose.

246 BMI (kg/m²) was calculated using the formula[21]: weight (kg) ÷ height² (m²); the homeostatic
247 model assessment of insulin resistance (HOMA-IR) was calculated using the formula[22]:
248 insulin (μU/L) × glucose (nmol/L)/22.5; and fatty liver index (FLI) was calculated using the
249 formula[23]:

$$250 \quad FLI = \frac{(e^{0.953 \cdot \log_e TG + 0.139 \cdot BMI + 0.718 \cdot \log_e GGT + 0.053 \cdot AC - 15.745})}{(1 + e^{0.953 \cdot \log_e TG + 0.139 \cdot BMI + 0.718 \cdot \log_e GGT + 0.053 \cdot AC - 15.745})} * 100$$

251 Daily Vitals

252 Daily vitals were collected onsite by trained clinical research staff every morning from BL
253 through EOR. Participants were asked to rest in a seated position with their arms elevated to
254 heart level on a table or pillow for five minutes prior to having their BP (Welch Allyn-Connex
255 ProBP 3400, Hill-Rom Holding Inc. Chicago, IL, USA), BT (Welch Allyn Sure Temp plus 690,
256 Hill-Rom Holding Inc. Chicago, IL, USA), peripheral oxygen saturation (SpO₂, Zacurate
257 500DL, Zacurate, Stafford, TX, USA), and pulse rate and rhythm (manually for 15 seconds or 1
258 min) measured. BW was self-reported using a floor scale (WW26, Conair LLC, Stamford, CT,
259 USA). Participants were also asked about hours of sleep, energy level, urination characteristics
260 (dysuria, difficulty, changes), nausea, presyncope, quantity of water intake, bowel movements
261 (frequency, characteristics), and any other symptoms for the previous 24 hours as well as about
262 any unresolved complaints.

263 Questionnaires

264 *SOS-Free Dietary Screener*

265 Adherence to the recommended SOS-Free Diet was assessed with a 27-question screener as
266 previously described.[15] The SOS-Free Dietary Screener was administered online at BL, 6wFU,
267 and 12mFU visits. A non-adherence score was calculated based on consumption of inclusionary
268 and exclusionary foods over the previous 30 days. The minimum non-adherence score is zero
269 (i.e., 100% adherent) and the maximum non-adherence score is 82.5 (i.e., 0% adherent).

270 *Treatment Acceptability Adherence Scale*

271 Acceptability of the treatment was assessed using the Treatment Acceptability/Adherence Scale
272 (TAAS).[17] The TAAS was administered online at EOF and 6wFU visits. The TAAS contains
273 10 questions with response options ranging from 1 (disagree strongly) to 4 (neither agree nor
274 disagree) to 7 (agree strongly). Negatively worded questions (#3-5, #7-8, #10) were reverse
275 scored and total scores were obtained by summing all answers. Scoring ranged from 70 to 10
276 with higher scores indicating greater treatment acceptability. Individual questions are shown
277 **SF1**.

278 *Food Acceptability Questionnaire*

279 Acceptability of foods permitted on the SOS-Free Diet was assessed using the Food
280 Acceptability Questionnaire.[18] The FAQ was administered online at BL, EOR, 6wFU, and
281 12mFU visits. The questionnaire contains 10 questions with response options ranging from 1
282 (not at all) to 7 (extremely). Negatively worded questions (#4 and #8) were reverse scored and
283 total scores were obtained by summing all answers. Scoring ranged from 70 to 10 with higher
284 scores indicating greater acceptability of permissible foods. Individual questions are shown in
285 **SF2**.

286 **Statistical Analysis**

287 This single-arm pre-post interventional trial evaluates changes in clinical parameters across
288 visits. The absence of a control group inhibits the ability to discern if observed changes result
289 from the intervention, natural progression, external influences, Hawthorne effects, or other
290 factors. Data cleaning and statistical analysis were conducted using R (R Core Team, 2022), with
291 descriptive statistics reported as medians and interquartile ranges (IQR).[24] Bivariate
292 relationships between clinical parameters were visualized through scatter plots. The statistical
293 analysis aimed to estimate within-group changes between visits (e.g., BL, EOF, EOR, 6wFU,
294 and 12mFU) and identify significant changes. The analysis employed random intercept
295 generalized linear mixed-effects models, with clinical parameters as dependent variables and
296 participant ID as the grouping variable. Age and sex served as fixed effect control variables in all
297 models; baseline hypertension status was also included for binary outcome models.

298 Models for continuous outcomes were fitted using lmerTest version 3.1.3,[25] while binary and
299 count outcomes used lme4 version 1.1.32.[26] Binary data were modeled using a binomial
300 family parameter with a logit link, and count data used a Poisson family parameter with a log
301 link. Regression coefficients for all clinical parameters, along with 95% confidence intervals
302 (CI), were derived from broom.mixed version 0.2.9.4.[27] Significance for continuous data was

303 determined when CIs excluded zero, and for binary and count data, when exponentiated CIs
304 excluded one. Missing data were addressed through complete case analysis where case is defined
305 as a visit within participant. Model diagnostics employed graphical methods via the
306 modelDiagnostics function from multilevelTools version 0.0.1.[28] Where diagnostics indicated
307 model assumption violations, results were compared between lmerTest and the Robust Scoring
308 Equations estimator (RSE) from robustlmm version 3.2.0[29; 30] with the Satterthwaite degrees
309 of freedom approximation from sjPlot version 2.8.14.[31] Discrepancies in effect magnitude,
310 direction, or significance led to RSE results being prioritized. The RSE method was not available
311 for binary or count outcomes.

312 After data collection was complete, a post-hoc simulation-based power analysis[32] was
313 conducted. This analysis used hypothetical population effect sizes and standard deviations[33]
314 derived from the SBP and BMI models in Table 4 of Gabriel et al.[15] The goal was to estimate
315 the sample size required to achieve 80% statistical power at an alpha level of 0.05 for parameter
316 estimates assessing within-group changes from BL to 6wFU visits. For SBP, the power analysis
317 indicated that 80% power could be attained with 32 participants. This calculation was based on
318 data simulated from a model with population effect sizes set as follows: -11.49 mmHg for EOF –
319 BL, -14.58 mmHg for EOR – BL, -7.68 mmHg for 6wFU – BL, and -1.92 mmHg for 12mFU –
320 BL. Since, Gabriel et al.[15] did not include a 12mFU visit, the 12mFU effect size of -1.92
321 mmHg represents a 25% reduction from the 6wFU effect. Additional model parameters included
322 0.21 mmHg per year for age and 0.73 mmHg for sex. The population standard deviations were
323 set at 10.58 mmHg for the group level and 10.55 mmHg for the residual standard deviation.
324 Adjusting the simulation to increase the magnitude of effect sizes associated with the visits by
325 10%, while maintaining other effect sizes and standard deviations as in the initial simulation,
326 resulted in achieving 80% power with a reduced sample size of 27 participants. For the
327 exploratory secondary endpoint BMI, the analysis demonstrated that 80% statistical power could
328 be reached with 27 participants. This was based on a model simulation with population effect
329 sizes as follows: -1.92 kg/m² for EOF – BL, -1.61 kg/m² for EOR – BL, -1.62 kg/m² for 6wFU –
330 BL, and -0.24 kg/m² for 12mFU – BL. The model also included age and sex effect sizes of -0.01
331 kg/m² per year and -1.10 kg/m², respectively. The population standard deviations were set at 7.07
332 kg/m² for the group level and 1.08 kg/m² for the residual standard deviation. These parameters
333 represented a 60% reduction in the magnitude of effect sizes associated with the visits and a
334 150% increase in the standard deviations, in comparison to the model that produced the BMI
335 results in Table 4 of Gabriel et al.[15]

336 The rates of change in clinical parameters were estimated using linear mixed-effect models[34]
337 implemented with Linear and Nonlinear Mixed Effects Models (nlme) version 3.1.160.[35] In
338 these models, the clinical parameter was designated as the dependent variable, the day of the
339 study phase as the fixed effect, and participant ID as the random intercept. Additionally, the fully
340 specified model included the day of the study phase as the random slope. This fully specified
341 model was preferred when both the Akaike Information Criterion (AIC) and Bayesian
342 Information Criterion (BIC) were lower compared to the parsimonious model, which did not
343 include the random slope. The parameter estimate for the day of study phase fixed effect was
344 interpreted as the rate of change for each clinical parameter. Separate models were fitted for
345 distinct study phases: prefeeding, fasting, and refeeding. For the body weight clinical parameter,
346 two periods of fasting were analyzed: early and late fasting. Estimates for body weight during

347 these fasting periods were derived from a linear mixed effects model that included day of study
348 phase, period of study phase, and their interaction as fixed effects. Participant ID was set as the
349 random intercept and day of study phase as the random slope in the model. The early fasting
350 period included days 1 to 5 and the late fasting period included the subsequent days. To assess
351 homogeneity of variance and normality of residuals, residual plots and quantile-quantile plots
352 were utilized, respectively. When violations of these assumptions were notable, RSEs[29] were
353 used with the Satterthwaite degrees of freedom approximation.[31]

354

355 **3 Results**

356 **Participant Characteristics**

357 Of the 29 eligible participants, there were 19 females and 10 males with a combined median
358 (IQR) age of 62 (58, 67) years (**Table 1**). At the BL visit, all participants had a diagnosis of stage
359 1 or 2 hypertension (HTN) and 15 (52%) were taking antihypertensive medications. Five (17%)
360 participants had medication-controlled SBP/DBP of <130/<80 mmHg, seven (24%) had a SBP
361 and/or DBP between 130-139/80-89 mmHg (stage 1), and 17 (59%) had a SBP and/or DBP
362 $\geq 140/\geq 90$ mmHg (stage 2; **Table 1**). The most common preexisting comorbidity was mixed and
363 unspecified hyperlipidemia (n=12; 45%) (**ST2**). At the BL visit, four (14%) participants were
364 normal weight, 10 (34%) were overweight, and 15 (52%) were obese (**Table 1**). At the 12mFU
365 visit there were 17 participants, of which, 12 were female and five were male with a median
366 (IQR) age of 63 (60, 69) years.

367 **Treatment & Visit Characteristics**

368 Participants stayed onsite at a residential fasting center in order to receive medical supervision
369 while prefeeding, fasting, and refeeding for a median (range) of 2 (1-4), 11 (7-40), and 5 (3-17)
370 days, respectively (**ST3**). Participants were instructed to continue eating an SOS-free diet while
371 offsite between EOR and 6wFU visits and did not receive further dietary instruction thereafter.
372 The 6wFU and 12mFU visits occurred at a median (range) of 45 (40-58) days after the EOR visit
373 and 364 (358, 383) days after the 6wFU visit, respectively (**ST3**). All participants completed BL,
374 EOF, and EOR visits (**Figure 1, ST1**), of which 2/29 participants had partially incomplete data at
375 EOF. Twenty-seven of the 29 participants attended the 6wFU visit, of which 2/27 had partially
376 incomplete data and 17/27 consented to attend the 12mFU visit (**ST1**). Of the 17 returning
377 participants, five voluntarily visited TNHC for additional interventions between 6wFU and
378 12mFU visits. Of these, two participants visited TNHC one time and three participants visited
379 two times, with a median (range) fasting and refeeding length of 10 (8, 13) and 6 (4, 9) days,
380 respectively. (**ST1, ST3**).

381 **Water-only Fasting and Refeeding Treatment Acceptability & SOS-Free Dietary** 382 **Adherence**

383 Participant acceptability of the entire fasting and refeeding intervention (BL to EOR) was
384 assessed using the Treatment Acceptability/Adherence Screener (TAAS) with scores ranging
385 from 10 (no acceptability/adherence) to 70 (full acceptability/adherence). Responses to

386 individual TAAS questions are shown in **SF1**. Median (IQR) scores were 67 (63, 70) and 66 (60,
387 69) at EOF and 6wFU visits, respectively.

388 Participant acceptability of the foods permitted on the SOS-Free Diet was assessed using the
389 Food Acceptability Questionnaire (FAQ) with scores ranging from 10 (no acceptability) to 70
390 (full acceptability). Responses to individual FAQ questions are shown in **SF2**. Median (IQR)
391 scores were 47 (44, 52), 49 (45, 58), 48 (42, 55), and 45 (32, 70) at BL, EOR, 6wFU, and
392 12mFU visits, respectively.

393 Participant adherence to the SOS-Free Diet during the six-week follow-up period was assessed
394 using a previously described dietary screener with scores ranging from zero (100% adherent) to
395 82 (0% adherent).[15] Responses to individual questions are in **ST4**. The mean (SD) score was
396 12 (10), 6 (3), and 6 (4) at BL, 6wFU, and 12mFU, respectively.

397 Overall, these results suggest that participants found fasting and refeeding at the residential
398 fasting center to be highly acceptable. The recommended diet was found to be moderately
399 acceptable and participants reported imperfect adherence that improved only slightly at 6wFU
400 and 12mFU visits compared to the period before the BL visit. Participants primarily increased
401 fruit and vegetable consumption and decreased animal products, added salt, and oil.

402 **Adverse Events Identified During Prefeeding, Fasting, and Refeeding**

403 Daily interviews and physical examinations as well as weekly hematology, serology, urinalyses,
404 and additional testing as indicated were used to identify AEs through the EOR visit. AEs were
405 classified into categories and grades using CTCAE v.5.0.[20] We identified 453 AEs, of which
406 381 (84%) were mild Grade 1 (G1), 64 (14%) were moderate Grade 2 (G2), and 8 (2%) were
407 severe Grade 3 (G3) events (**Table 2**). There were no Grade 4 (life-threatening), Grade 5 (death),
408 or serious AEs. There were 11 (2%), 350 (77%), and 92 (20%) AEs during prefeeding, fasting,
409 and refeeding, respectively (**Table 2**). G1, G2, and G3 were the highest grade AE (HGAE)
410 experienced by 7% (2/29), 69% (20/29), and 24% (7/29) of participants, respectively.

411 **Supplemental Table 5** shows AEs experienced by >10% of participants (N=29) by treatment
412 stage. Overall, the top five events were mild-to-moderate fatigue, mild decrease in blood
413 bicarbonate, mild decrease in BUN/Creatinine, mild-to-moderate high blood pressure, and mild-
414 to-moderate nausea (**ST5, ST6**). The three most frequently occurring events during fasting were
415 fatigue, hypertension, and decreased blood bicarbonate. There were 15 AE classifications that
416 only occurred during fasting (**ST5**) including presyncope and changes in blood chemistry and/or
417 blood count identified by CMP and CBC analysis (**ST7 - ST10**). During refeeding, fatigue was
418 the most common event and diarrhea occurred only during refeeding (**ST5**). As expected, 4/5
419 hyperglycemia events occurred during refeeding. The other hyperglycemic event was identified
420 at the EOF visit and may be due to an unreported protocol deviation.

421 Total AEs, associated system organ class, and event outcome are shown in **ST6**. The most
422 frequently occurring G1 events were fatigue (n=60/381), dizziness (n=23/381), decreased blood
423 bicarbonate (n=22/381), decreased BUN/creatinine ratio (n=18/381), nausea (n=13/381), and
424 decreased chloride (n=13/381). Of the 381 G1 events, 33 were unresolved at EOR or 6wFU
425 visits, and the outcome of 19/381 G1 events were unknown due to either unrepeated tests (9/19)

426 or participant drop out (10/19).. The most frequently occurring G2 events were fatigue
427 (n=19/64), hypertension (16/64), and presyncope (n=10/64). All of the G2 events resolved while
428 onsite (n=63/64) or before the 6wFU visit (n=1/64). Of the eight G3 events, seven were
429 hypertensive events and one was a low neutrophil count. All G3 hypertensive events resolved
430 before the EOR visit, but it is unknown if the low neutrophil count resolved due to participant
431 drop out at the 6wFU visit.

432 **Deviations in Water-only Fasting**

433 Twenty-seven of 29 participants (93%) completed at least seven consecutive days of fasting, of
434 these 17/27 (63%) fasted solely on water, 9/27 fasted on water and vegetable broth (VB), and
435 1/27 (4%) fasted only on VB (**ST3**). Fasting on VB provides only 80 kcal/day and does not affect
436 ketosis. Therefore, it is considered similar to water-only fasting. Of the 10 deviations with VB, at
437 least six were due to a treatment emergent AE, which included G2 presyncope (n=3), G1
438 gastroesophageal reflux (n=1), G1 hypokalemia (n=1), and G1 dry mouth (n=1). The one
439 participant who fasted entirely on VB did so because of preexisting cardiac arrhythmia. Of the
440 two participants who did not complete at least seven consecutive days of fasting, one temporarily
441 interrupted the fast with potato/zucchini blend due to a G2 gastroesophageal reflux event and one
442 modified the fast with vegetable and fruit juice due to G2 hypoglycemia (**ST3**). Additionally,
443 two of the 27 who completed at least seven consecutive fasting days had their fast prematurely
444 terminated after day seven due to an AE, which included one participant with a G2 nausea event
445 and one with concurrent G1 hypokalemia, and G1 electrocardiogram QT corrected prolonged
446 events.

447 **Additional Hematology, Serology, and Urinalysis for AE recording**

448 In addition to what is normally collected according to clinical protocol, CBC and CMP were
449 performed at BL, EOF, and EOR visits. CBC and CMP were also analyzed at 6wFU and 12mFU
450 visits. AEs resulting from abnormal CBC, CMP, and urinalysis values for individual participants
451 are described above and in **ST5**, **ST6**. Throughout the study, median values for CBC variables
452 remained within normal range (**ST7**, **ST8**). Median (IQR) CMP values reached abnormal values
453 and included low BUN [6 (4, 8) mg/dL] for participants >60 years old at the EOR visit, low
454 BUN/creatinine ratio at EOF [8 (7, 11) mg/dL] and EOR [7 (6, 9) mg/dL] visits for the entire
455 population, and decreased carbon dioxide [17 (15, 20) mmol/L] at the EOF visit (**ST9**, **ST10**).
456 Median values increased to the normal range for carbon dioxide at the EOR visit and for BUN
457 and BUN/creatinine ratio at the 6wFU visit. Significant estimated changes for some CMP
458 variables may be clinically meaningful even though the median value remained within normal
459 limits. For example, baseline sodium significantly decreased by an estimated (95% CI) -2.79 (-
460 4.06, -1.53) mmol/L by the end of fasting and there were four transient grade 1 hyponatremia
461 events during fasting, but the end-of-fast median (IQR) sodium level of 141 (139, 143) mmol/L
462 remained within normal limits (134-144 mmol/L). Twenty-four-hour dipstick urinalysis was also
463 assessed weekly by the attending physician to monitor fasting as well as at BL, EOF, and EOR
464 visits. As expected, ketones increased and pH decreased during fasting but reverted to baseline
465 upon refeeding. Values for other variables were unremarkable (**ST11**).

466 **Changes in BW, BMI, AC, and Vital Signs**

467 There was an average BW loss of -0.54 kg/day while fasting and an average gain of 0.23 kg/day
468 while refeeding (ST12, SF3A). Accordingly, baseline median (IQR) BW reduced from 86.6
469 (80.1, 97.6) kg to 79.1 (72.4, 87.8) kg and 81.4 (73.8, 88.7) kg at EOF and EOR visits,
470 respectively (Table 3, Figure 4A). The estimated loss (95% CI) between BL and 6wFU visits
471 was -6.72 (-7.87, -5.58) kg, which was sustained at the 12mFU visit (Table 3, ST13). Median
472 BMI significantly decreased from 31.0 (26.5, 33.2) kg²/m² at the BL visit to 28.4 (23.5, 31.1)
473 kg²/m² at the 12mFU visit (Table 3, ST13, Figure 4B). The number (%) of participants that
474 were normal weight, overweight, and obese was 4 (14), 10 (34), and 15 (52) at the BL visit and 5
475 (29), 7 (41), 5 (29) at the 12mFU visit, respectively (ST14). In females, baseline median (IQR)
476 AC reduced from 100.5 (91.8, 108.7) to 91.5 (86.7, 101.0) at the EOF visit and to 90.6 (85.0,
477 95.0) cm at the 12mFU visit (Figure 4C, Table 3, ST13). In males, baseline median (IQR) AC
478 reduced from 100.3 (95.7, 107.3) cm to 90.8 (85.8, 100.0) at the EOF visit and to 91.0 (81.3,
479 95.0) cm at the 12mFU visit. Overall, this corresponded to an estimated AC loss (95% CI) of -
480 7.92 (-9.58, -6.26) cm between BL and 12mFU visits (ST13). Pulse, SpO₂, and BT were
481 measured daily while participants were onsite (ST12, ST15). There was a significant increase in
482 median pulse from BL to EOF visits corresponding to an estimated rate of change of 0.55
483 beats/min per day during fasting (ST16, ST12).

484 **Changes in SBP, DBP, and Anti-hypertensive Medication Use**

485 During prefeeding and fasting, SBP reduced by an average of -9 mmHg/day and -1 mmHg/day,
486 respectively (ST12, SF3B). DBP also significantly reduced during fasting by -0.3 mmHg per day
487 (ST12, SF3C). Overall, baseline median (IQR) SBP/DBP reduced from 142/81 (131/76, 162/90)
488 mmHg to 114/75 (110/72, 124/80) mmHg and 113/77 (110/72, 126/84) at EOF and EOR visits,
489 respectively (Table 3, ST13). The significant reductions were sustained at the 6wFU and 12mFU
490 visits. The estimated loss (95% CI) in SBP/DBP from the BL visit was -19.19/-5.13 (-26.32/-
491 8.77, -12.03/-1.46) and -17.20/-8.89 (-25.42/-13.09, -8.99/-4.67) mmHg at 6wFU and 12mFU
492 visits, respectively (ST13).

493
494 At the BL visit, 15/29 (52%) participants were taking 19 anti-hypertensive medications; 11/15
495 were taking one and 4/15 were taking two medications (ST17). Only 5/15 (33%) had achieved a
496 medication-controlled SBP/DBP of <130/80 mmHg (Table 3, Figure 4). During the prefeeding
497 period, all participants were tapered completely off anti-hypertensive medications by a trained
498 physician according to their individual medical needs and remained off medications while at the
499 residential fasting center. Participants' medication use after leaving the fasting center was
500 determined independently by their primary care physician. Fourteen of the 15 participants who
501 were taking anti-hypertensive medications at the BL visit returned for the 6wFU visit, of them
502 only 1/14 was taking one anti-hypertensive medication at a reduced dose (ST17, Figure 4). Ten
503 of the 15 participants who were taking anti-hypertensive medications at the BL visit returned for
504 the 12mFU visit, of them 6/10 were taking anti-hypertensive medications (ST17, Figure 4).
505 Figure 4 shows the SBP/DBP distribution of medicated and unmedicated participants at each
506 study visit.

507 **Changes in Select Cardiometabolic Markers**

508 Total cholesterol, HDL, LDL, VLDL, triglycerides, hsCRP, insulin, GGT, as well as calculated
509 HOMA-IR and FLI were also measured at each study visit (Table 3). At BL, only median total

510 cholesterol, LDL, and FLI were outside of the normal limits. Median (IQR) total cholesterol
511 normalized during refeeding to 4.71 (4.12, 5.52) mmol/L and was sustained at 6wFU and 12mFU
512 visits. Median LDL remained slightly elevated throughout the study and median triglycerides
513 increased slightly out of normal limits at the EOR visit but normalized again at the 6wFU visit.
514 Median insulin remained within normal limits throughout the study but significantly increased at
515 the EOR visit and normalized again by the 6wFU visit. Median (IQR) FLI, which was
516 abnormally high at the BL visit, significantly decreased at 6wFU and 12mFU visits (**Table 3,**
517 **ST13, Figure 4D**).

518

519 **4 Discussion**

520 These data contribute to a growing body of evidence suggesting that medically supervised
521 prolonged water-only fasting followed by whole-plant-food refeeding may be a safe and feasible
522 treatment option for various health conditions, particularly obesity and hypertension.[12; 13; 15;
523 36; 37] Importantly, the fasting and refeeding intervention in this study was conducted in a
524 residential setting using a protocol in which participants had access to medical support 24 hours
525 per day and are individually examined twice daily to identify potentially serious complications.
526 Even though the prolonged intervention takes place in a residential setting, participants reported
527 that they found it to be highly acceptable and preferable to conventional treatment with anti-
528 hypertensive medications. Furthermore, the vast majority of participants were able to complete at
529 least seven consecutive days of fasting, suggesting that the intervention is feasible.

530 There were no higher grade or serious adverse events identified in this study. Furthermore, the
531 AE data reported in this hypertensive population are in agreement with previously reported
532 retrospective data from a larger mixed normotensive and hypertensive population using the same
533 fasting protocol.[14] Both studies identified that the most commonly reported AEs (occurring in
534 >25% of participants) included transient mild or moderate fatigue, nausea, presyncope, dizziness,
535 headache, and insomnia.[14] The present study also utilized hematology and serology to
536 thoroughly screen for AEs and identified some commonly occurring AEs not previously
537 reported. For example, 72% of participants experienced mild decreased blood bicarbonate while
538 fasting potentially due to the overproduction of ketoacids.[38] Symptoms of decreased blood
539 bicarbonate include fatigue and nausea, which could potentially explain, at least in part, the high
540 rates of fatigue and nausea commonly reported while fasting.

541 HTN was also amongst the most commonly identified AEs in both studies. It is worth
542 underscoring that fasting does not increase blood pressure in normotensive individuals.[39]
543 Seven of the eight G3 events identified in this study were HTN and occurred during fasting,
544 which is unsurprising given that this population had uncontrolled HTN and/or were weaned off
545 anti-hypertensive medications before starting to fast. All of the G3 HTN events resolved while
546 refeeding. The other G3 event was a low neutrophil count during refeeding that progressed from
547 a G1 event during prefeeding. At the EOR visit, the participant's WBC count had also decreased
548 to a G1 event. Overall, we observed a trend of significantly decreased WBC count (**ST7, ST8**) at
549 EOR, but the median value did not decrease below the lower normal level and abnormal values
550 were not associated with any clinical outcomes. Previous research suggests that prolonged
551 fasting induces stem cell regeneration and leads to a transient reduction in WBC count such that

552 the body discards old WBCs before the immune system is replenished with new ones.[40] We do
553 not know the relevance of this or other changes in CBC or CMP, but the results are in line with
554 previous reports and warrant a more thorough analysis beyond the scope of this manuscript.[41]

555 Similar to previous reports, we observed clinically meaningful and significant reductions in
556 median BP, BW, BMI, AC, and FLI that correlated with the intervention and were sustained at
557 the 6wFU.[15] Results were also sustained at an unanticipated visit 12 months after the 6wFU
558 visit. These preliminary data are confounded by low retention and that 5/17 participants
559 underwent at least one other fasting and refeeding intervention during the study year.
560 Nonetheless, the long-term BW loss data is especially encouraging given the long-held belief
561 that weight lost through fasting is quickly regained.[42]

562 Although the study was not designed to test the effectiveness of fasting and refeeding in the
563 treatment of hypertension, we observed that median unmedicated SBP reduced from Stage 2
564 HTN at the BL visit to normotensive by the EOR visit. At the 6wFU visit, only one participant
565 had resumed anti-hypertensive medications and 38% of participants had sustained an SBP/DBP
566 of <120/80 mmHg, with the largest reductions observed in participants who had stage 2 HTN at
567 the BL visit. This large reduction was observed even though 5/17 participants with stage 2 HTN
568 on enrollment continued to have stage 2 HTN six weeks after the intervention. The reductions in
569 BP correlate with the timing of the intervention and are in agreement with other studies, [12; 13;
570 15; 36; 37] setting a precedent for future randomized controlled trials. Results from the 12mFU
571 visit are inconclusive due to participant dropout, but the median SBP remained below 130
572 mmHg and of the 6/17 participants who resumed anti-hypertensive medications, only one had
573 SBP below 120 mmHg.

574 These results are encouraging, but the study has several limitations that should be addressed in
575 future research. A major limitation is the potential for selection bias since the small number of
576 participants were recruited from existing patients at a single fasting center and the majority of
577 enrolled participants were post-menopausal women. Therefore, the results from this “self-
578 selected” population may not be representative of the general hypertensive population. The study
579 also lacks a diet control group and/or usual care comparison group. Therefore, it is inconclusive
580 as to what long-term results are attributable to diet alone and how the intervention compares to
581 standard interventions (e.g., combined-therapy anti-hypertensive medications). Furthermore, the
582 study was not powered to assess changes in cardiometabolic markers and only 59% of
583 participants re-enrolled for the 12-month follow-up visit. Future studies should aim to enroll and
584 randomize a sufficient number of participants from a more general hypertensive population and
585 include appropriate control populations as well as hold more frequent, planned study visits.
586 Another important methodological limitation is that BP data are based on single rather than 24-
587 hour ambulatory BP measurements.[43] The effect of these methodological limitations on study
588 outcomes is unknown, but these results are comparable to other reports in different
589 populations.[12; 13; 36]

590

591 **Conclusion**

592 Hypertension is the most common chronic disease worldwide, and when uncontrolled it is a risk
593 factor for developing cardiovascular and other diseases. Standard medical care typically includes
594 anti-hypertensive medications that only minimally lower overall health risk reductions, may be
595 accompanied with serious side effects, have low adherence, and a high life-time cost.[4; 8; 44;
596 45] Our results suggest that prolonged water-only fasting followed by partial adherence to an
597 SOS-free diet may be a safe and feasible alternative that results in sustained reductions in BMI
598 and BP. These findings are in support of additional research to include a more diverse
599 population, optimize treatment length and frequency, determine the effects of diet and other
600 lifestyle modifications on sustained outcomes, and compare this intervention to standard
601 treatment.

602

603 5 Figures

604 **Figure 1. Enrollment and participation flow diagram.** See “Participant Enrollment and Study
605 Protocol” in the “Materials and Methods” section and “Participant Characteristics” in the
606 “Results” section for details on eligibility and data collection. BL, baseline; EOF, end-of-fast;
607 EOR, end-of-refeed; 6wFU, six-week follow-up; 12mFU, 12-month follow-up.

608 **Figure 2. SBP (A, C, E) and DBP (B, D, F) by visit of all (A, B), unmedicated (C, D) and
609 medicated (E, F) participants at BL.** Circles and squares in panels C, D, E, F represent
610 unmedicated and medicated SBP/DBP, respectively. Participants who attended the 12mFU visit
611 (n=17) are depicted as closed (black) symbols. Horizontal dotted lines represent severity of
612 HTN: SBP 120-129 mmHg, elevated blood pressure; SBP/DBP \geq 130/80 mmHg, Stage 1 HTN;
613 SBP/DBP \geq 140/90 mmHg, Stage 2 HTN. 3/29 and 12/29 participants did not provide data at
614 6wFU and 12mFU visits, respectively. SBP, systolic blood pressure; DBP, diastolic blood
615 pressure; mmHg, millimeter mercury; BL, baseline; EOF, end-of-fast; EOR, end-of-refeed;
616 6wFU, six-week follow-up; 12mFU, 12-month follow-up; HTN, hypertension.

617

618 6 Tables

Table 1. Select Baseline Characteristics

Total Participants, N	29
Total Medicated [^] Participants, n (%)	15 (52)
Female, n (%)	19 (66)
Median (IQR) Age, y	62 (58, 67)
Medicated [^] SBP/DBP = <130/80 mmHg, n (%)	5 (17)
SBP/DBP* = 130-139/80-89 mmHg, n (%)	7 (24)
SBP/DBP ⁺ = \geq 140/90, n (%)	17 (59)
Normal Weight BMI, n (%)	4 (14)
Overweight BMI, n (%)	10 (34)
Obese BMI, n (%)	15 (52)

N, the total number of participants; n, a subset of 29 participants; %, percentage; IQR, interquartile range; y, years; SBP, systolic blood pressure; DBP, diastolic blood pressure: Stage 1 HTN = 130-139/80-89 mmHg, Stage 2 HTN = \geq 140/90 mmHg; BMI, body mass index: normal weight, 18.5-<25 kg/m²; overweight, 25-<29 kg/m²; obese \geq 30 kg/m². [^]Medicated with anti-hypertensive medications. ^{*}2/7 participants were taking anti-hypertensive medications. ⁺8/17 participants using anti-hypertensive medications.

619

Table 2. Total Adverse Events by Grade & Treatment Phase

AE Grade	N (%)			
	Prefeeding	Fasting	Refeeding	All Phases
1	9	289	83	381 (84)
2	2	54	8	64 (14)
3	0	7	1	8 (2)
4	0	0	0	0
5	0	0	0	0
Total	11 (2)	350 (77)	92 (20)	453 (100)

N (%), number and percentage of total adverse events; AE, adverse event; Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, life-threatening; Grade 5, death. There were no Grade 4 or 5 events.

620

Table 3. Cardiometabolic Biomarkers by Visit

	Median (IQR)				
	BL	EOF ^a	EOR	6wFU [#]	12mFU
BW, kg	86.6 (80.1, 97.6)	79.1 (72.4, 87.8)	81.4 (73.8, 88.7)	80.3 (75.3, 85.7)	80.4 (72.1, 88.9)
BMI, kg²/m² 18.5-24.9	31.0 (26.5, 33.2)	28.0 (23.6, 30.1)	28.4 (24.4, 30.8)	29.0 (24.2, 30.2)	28.4 (23.5, 31.1)
AC, cm					
All	100.5 (92.0, 109.0)	91.5 (86.4, 101.0)	94.3 (88.0, 102.0)	94.9 (87.0, 102.0)	90.6 (85.0, 95.0)
Female: <88	100.5 (91.8, 108.7)	91.5 (86.7, 101.0)	93.5 (88.1, 102.0)	94.3 (86.5, 101.3)	90.3 (86.1, 93.7)
Male: <102	100.3 (95.7, 107.3)	90.8 (85.8, 100.0)	95.0 (87.4, 102.6)	96.1 (91.0, 102.8)	91.0 (81.3, 95.0)
SBP, mmHg <120	142 (131, 162)	114 (110, 124)	113 (110, 126)	121 (113, 136)	127 (116, 132)
DBP, mmHg <80	81 (76, 90)	75 (72, 80)	77 (72, 84)	78 (74, 83)	73 (71, 76)
Total Cholesterol, mmol/L 2.59 - 5.15	5.26 (4.35, 5.80)	5.39 (4.66, 6.54)	4.71 (4.12, 5.52)	4.97 (4.38, 5.44)	4.92 (4.38, 6.16)
HDL Cholesterol, mmol/L > 1.01	1.19 (0.98, 1.42)	1.11 (0.97, 1.31)	1.14 (0.96, 1.40)	1.20 (0.96, 1.42)	1.42 (1.06, 1.50)
VLDL Cholesterol, mmol/L 0.13 - 1.04	0.57 (0.47, 0.75)	0.57 (0.49, 0.66)	0.67 (0.62, 0.88)	0.60 (0.49, 0.77)	0.52 (0.41, 0.62)
LDL Cholesterol, mmol/L < 2.56	3.24 (2.64, 3.81)	3.76 (2.82, 4.48)	2.90 (2.25, 3.60)	3.15 (2.61, 3.58)	3.00 (2.43, 3.86)
Triglycerides, mmol/L < 1.68	1.41 (1.08, 1.84)	1.42 (1.18, 1.58)	1.71 (1.50, 2.19)	1.46 (1.15, 1.87)	1.21 (0.96, 1.53)
Insulin, pmol/L 16 -149	42 (34, 78)	25 (17, 38)	52 (40, 79)	59 (31, 75)	51 (32, 63)
In (Insulin, pmol/L) 2.7 - 5.0	3.7 (3.5, 4.4)	3.2 (2.8, 3.6)	4.0 (3.7, 4.4)	4.1 (3.4, 4.3)	3.9 (3.5, 4.1)
HOMA-IR < 1.9	1.7 (1.3, 2.9)	0.7 (0.5, 1.3)	2.1 (1.4, 3.4)	2.3 (1.1, 3.1)	2.0 (1.0, 2.6)
In (HOMA-IR) < 0.64	0.51 (0.23, 1.06)	-0.33 (-0.64, 0.24)	0.73 (0.34, 1.22)	0.83 (0.13, 1.13)	0.69 (0.03, 0.95)
GGT, nmol/(s-L) < 1000	317 (233, 433)	267 (208, 383)	267 (200, 400)	292 (238, 408)	217 (183, 400)
In (GGT, nmol/(s-L)) < 6.90	5.76 (5.45, 6.07)	5.59 (5.34, 5.95)	5.59 (5.30, 5.99)	5.68 (5.47, 6.01)	5.38 (5.21, 5.99)
Fatty Liver Index < 30	60.1 (38.5, 84.9)	39.2 (19.3, 60.1)	54.6 (26.0, 74.6)	48.1 (23.6, 70.7)	34.9 (23.0, 52.0)
hsCRP, mg/L < 3.0	1.67 (0.65, 3.40)	3.09 (1.23, 4.87)	1.32 (0.64, 3.04)	0.84 (0.63, 1.49)	1.03 (0.65, 1.95)
In (hsCRP, mg/L) < 1.09	0.51 (-0.43, 1.22)	1.13 (0.20, 1.58)	0.28 (-0.45, 1.11)	-0.18 (-0.46, 0.40)	0.03 (-0.43, 0.67)

Normal reference ranges are listed below each variable. (1) At BL, EOF, and EOR, there were 29 participants. At the 6wFU and 12mFU, there were 26 and 17 participants, respectively. IQR, interquartile range; BL, baseline; EOF, end-of-fast; EOR, end-of-refeed; 6wFU, six-week follow-up; 12mFU, 12-month follow-up; BW, body weight; BMI, body mass index; kg/m², kilogram per square meter; AC, abdominal circumference; cm, centimeter; SBP, systolic blood pressure; DBP, diastolic blood pressure; mmHg, millimeter mercury; kg, kilogram; LDL, low-density lipoprotein; HDL, high-density lipoprotein; VLDL, very-low-density lipoprotein; mmol/L, millimole per liter; pmol/L, picomole per liter; HOMA-IR, homeostatic model assessment for insulin resistance; GGT, gamma-glutamyl transferase; nmol/(s·L), nanomole per second and liter; hsCRP, high-sensitivity C-reactive protein; mg/L, milligram per liter; ln, natural logarithm. ^aTwo participants began refeeding before EOF blood draw and were excluded from all serology. ^bThree participants did not excluded from the 6wFU analyses and of the remaining 26, one only provided values for blood pressure.

621

622 **Supplementary Materials:** Supplemental Materials include **Supplemental Tables:** ST1.
623 Enrollment and Visit Characteristics; ST2. Baseline ICD-10 Diagnosis & Code by Sex; ST3.
624 Treatment Characteristics; ST4. SOS-Free Diet Screener Serving Quantity Reported by Category
625 at BL, 6wFU, and 12mFU; ST5. Adverse Events Occurring in $\geq 10\%$ of Participants by
626 Treatment Stage and Grade; ST6. Total Adverse Events by Classification, Grade, and Outcome;
627 ST7. CBC by Visit; ST8. Significance of Differences for CBC; ST9. CMP by Visit; ST10.
628 Significance of Differences for CMP; ST11. 24-hour Dipstick Urinalysis by Visit; ST12. Daily
629 Rate of Change for Body Weight, Blood Pressure, and Vital Signs; ST13. Significance of
630 Difference for Cardiometabolic Biomarkers; ST14. Weight Class by Visit; ST15. Vital Signs by
631 Visit; ST16. Significance of Differences for Vital Signs; ST17. Anti-Hypertensive Medication
632 Use at BL, 6wFU, and 12mFU; **Supplemental Figures:** SF1: Percentage of participants
633 responding to individual TAAS questions; SF2: Percentage of participants responding to
634 individual FAQ questions; SF3: Daily measurements during prefeeding, fasting, and refeeding of
635 BW (A), SBP (B), and DBP (C); SF4: BW (A), BMI (B), AC (C), and FLI (D) by visit.

636

637 **Non-standard Abbreviations and Acronyms**

638	BL	Baseline
639	EOF	End of fast
640	EOR	End of refeed
641	FAQ	Food Acceptability Questionnaire
642	FU	Follow up
643	SOS	Salt, oil, and sugar
644	TAAS	Treatment Adherence/Acceptability Scale
645	VB	Vegetable Broth

646

647 **Acknowledgments:** We would like to thank the dedicated staff at the TrueNorth Health Center,
648 especially Justin Wise, Rie Schur, Ahmed Deen, Mara Gilbert, Faye Alexandrakis, and Haley
649 Ramsey, for their contributions with participant monitoring, recording of adverse events, and
650 REDCap instrument development. We also thank David Goldman for critically reviewing this
651 manuscript.

652 **Funding:** This research received no external funding.

653 **Author Contributions:** Conceptualization, TRM, ES, and ACG; Methodology, TRM, ACG,
654 MN; Formal Analysis, MN and EZ; Validation, MN; Investigation, SG, EZ, and NT; Resources,
655 TRM, SG, and EZ; Data Curation, EZ, SG, and MN; Writing – Original Draft Preparation, EZ
656 and TRM; Writing – Review & Editing, TRM, EZ, SG, MN, NT, ES, and A.C.G.; Visualization,
657 EZ, MN, and TRM; Supervision, TRM; Project Administration, TRM, SG, and EZ; Funding
658 Acquisition, ACG.

659 **Institutional Review Board Statement:** The study was conducted according to the guidelines of
660 the Declaration of Helsinki, and approved by the Institutional Review Board of the TrueNorth
661 Health Foundation (TNHF2020-1HTN, August 16, 2020 and TNHF2021-1HTNFU, October 28,
662 2021).

663 **Informed Consent Statement:** Informed consent was obtained from all subjects involved in the
664 study.

665 **Data Availability Statement:** Data is available upon request to the corresponding author.

666 **Conflicts of Interest:** ACG is the owner of the TrueNorth Health Center and President of the
667 Board of Directors of the TrueNorth Health Foundation. All other authors declare no conflict of
668 interest.

669

670 **References**

671 [1] Y. Ostchega, C.D. Fryar, T. Nwankwo, and D.T. Nguyen, Hypertension Prevalence Among Adults Aged
672 18 and Over: United States, 2017-2018. NCHS Data Brief (2020) 1-8.

673 [2] E. Oliveros, H. Patel, S. Kyung, S. Fugar, A. Goldberg, N. Madan, and K.A. Williams, Hypertension in
674 older adults: Assessment, management, and challenges. *Clin Cardiol* 43 (2020) 99-107.

675 [3] S.S. Franklin, M.G. Larson, S.A. Khan, N.D. Wong, E.P. Leip, W.B. Kannel, and D. Levy, Does the
676 relation of blood pressure to coronary heart disease risk change with aging? The Framingham
677 Heart Study. *Circulation* 103 (2001) 1245-9.

678 [4] E.B. Kirkland, M. Heincelman, K.G. Bishu, S.O. Schumann, A. Schreiner, R.N. Axon, P.D. Mauldin, and
679 W.P. Moran, Trends in Healthcare Expenditures Among US Adults With Hypertension: National
680 Estimates, 2003-2014. *J Am Heart Assoc* 7 (2018).

681 [5] P.K. Whelton, R.M. Carey, W.S. Aronow, D.E. Casey, Jr., K.J. Collins, C. Dennison Himmelfarb, S.M.
682 DePalma, S. Gidding, K.A. Jamerson, D.W. Jones, E.J. MacLaughlin, P. Muntner, B. Ovbiagele, S.C.
683 Smith, Jr., C.C. Spencer, R.S. Stafford, S.J. Taler, R.J. Thomas, K.A. Williams, Sr., J.D. Williamson,
684 and J.T. Wright, Jr., 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA
685 Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in
686 Adults: A Report of the American College of Cardiology/American Heart Association Task Force
687 on Clinical Practice Guidelines. *J Am Coll Cardiol* 71 (2018) e127-e248.

688 [6] M.D. Chobufo, V. Gayam, J. Soluny, E.U. Rahman, S. Enoru, J.B. Foryoung, V.N. Agbor, A. Dufresne,
689 and T. Nfor, Prevalence and control rates of hypertension in the USA: 2017-2018. *Int J Cardiol*
690 *Hypertens* 6 (2020) 100044.

691 [7] A. Albasri, M. Hattle, C. Koshiaris, A. Dunnigan, B. Paxton, S.E. Fox, M. Smith, L. Archer, B. Levis, R.A.
692 Payne, R.D. Riley, N. Roberts, K.I.E. Snell, S. Lay-Flurrie, J. Usher-Smith, R. Stevens, F.D.R. Hobbs,

- 693 R.J. McManus, J.P. Sheppard, and S. investigators, Association between antihypertensive
694 treatment and adverse events: systematic review and meta-analysis. *BMJ* 372 (2021) n189.
- 695 [8] C.L.B. Ho, M. Breslin, J. Doust, C.M. Reid, and M.R. Nelson, Effectiveness of blood pressure-lowering
696 drug treatment by levels of absolute risk: post hoc analysis of the Australian National Blood
697 Pressure Study. *BMJ Open* 8 (2018) e017723.
- 698 [9] S.S. Virani, A. Alonso, H.J. Aparicio, E.J. Benjamin, M.S. Bittencourt, C.W. Callaway, A.P. Carson, A.M.
699 Chamberlain, S. Cheng, F.N. Delling, M.S.V. Elkind, K.R. Evenson, J.F. Ferguson, D.K. Gupta, S.S.
700 Khan, B.M. Kissela, K.L. Knutson, C.D. Lee, T.T. Lewis, J. Liu, M.S. Loop, P.L. Lutsey, J. Ma, J.
701 Mackey, S.S. Martin, D.B. Matchar, M.E. Mussolino, S.D. Navaneethan, A.M. Perak, G.A. Roth, Z.
702 Samad, G.M. Satou, E.B. Schroeder, S.H. Shah, C.M. Shay, A. Stokes, L.B. VanWagner, N.Y. Wang,
703 C.W. Tsao, E. American Heart Association Council on, C. Prevention Statistics, and S. Stroke
704 Statistics, Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart
705 Association. *Circulation* 143 (2021) e254-e743.
- 706 [10] N.T. Artinian, G.F. Fletcher, D. Mozaffarian, P. Kris-Etherton, L. Van Horn, A.H. Lichtenstein, S.
707 Kumanyika, W.E. Kraus, J.L. Fleg, N.S. Redeker, J.C. Meininger, J. Banks, E.M. Stuart-Shor, B.J.
708 Fletcher, T.D. Miller, S. Hughes, L.T. Braun, L.A. Kopin, K. Berra, L.L. Hayman, L.J. Ewing, P.A.
709 Ades, J.L. Durstine, N. Houston-Miller, L.E. Burke, and N. American Heart Association Prevention
710 Committee of the Council on Cardiovascular, Interventions to promote physical activity and
711 dietary lifestyle changes for cardiovascular risk factor reduction in adults: a scientific statement
712 from the American Heart Association. *Circulation* 122 (2010) 406-41.
- 713 [11] A. Dhakal, C.T. K, and M. Neupane, Adherence to lifestyle modifications and its associated factors in
714 hypertensive patients. *J Clin Nurs* 31 (2022) 2181-2188.
- 715 [12] A. Goldhamer, D. Lisle, B. Parpia, S.V. Anderson, and T.C. Campbell, Medically supervised water-only
716 fasting in the treatment of hypertension. *J Manipulative Physiol Ther* 24 (2001) 335-9.
- 717 [13] A.C. Goldhamer, D.J. Lisle, P. Sultana, S.V. Anderson, B. Parpia, B. Hughes, and T.C. Campbell,
718 Medically supervised water-only fasting in the treatment of borderline hypertension. *J Altern*
719 *Complement Med* 8 (2002) 643-50.
- 720 [14] J.S. Finnell, B.C. Saul, A.C. Goldhamer, and T.R. Myers, Is fasting safe? A chart review of adverse
721 events during medically supervised, water-only fasting. *BMC Complement Altern Med* 18 (2018)
722 67.
- 723 [15] S. Gabriel, M. Ncube, E. Zeiler, N. Thompson, M.C. Karlsen, D.M. Goldman, Z. Glavas, A. Beauchesne,
724 E. Scharf, A.C. Goldhamer, and T.R. Myers, A Six-Week Follow-Up Study on the Sustained Effects
725 of Prolonged Water-Only Fasting and Refeeding on Markers of Cardiometabolic Risk. *Nutrients*
726 14 (2022).
- 727 [16] T.R. Myers, B. Saul, M. Karlsen, A. Beauchesne, Z. Glavas, M. Ncube, R. Bradley, and A.C.
728 Goldhamer, Potential Effects of Prolonged Water-Only Fasting Followed by a Whole-Plant-Food
729 Diet on Salty and Sweet Taste Sensitivity and Perceived Intensity, Food Liking, and Dietary
730 Intake. *Cureus* 14 (2022) e24689.
- 731 [17] I. Milosevic, H.C. Levy, G.M. Alcolado, and A.S. Radomsky, The Treatment Acceptability/Adherence
732 Scale: Moving Beyond the Assessment of Treatment Effectiveness. *Cogn Behav Ther* 44 (2015)
733 456-69.
- 734 [18] A.D. Fruge, K.S. Smith, A.J. Riviere, W. Demark-Wahnefried, A.E. Arthur, W.M. Murrain, C.D.
735 Morrow, R.D. Arnold, and K. Braxton-Lloyd, Primary Outcomes of a Randomized Controlled
736 Crossover Trial to Explore the Effects of a High Chlorophyll Dietary Intervention to Reduce Colon
737 Cancer Risk in Adults: The Meat and Three Greens (M3G) Feasibility Trial. *Nutrients* 11 (2019).
- 738 [19] P.A. Harris, R. Taylor, R. Thielke, J. Payne, N. Gonzalez, and J.G. Conde, Research electronic data
739 capture (REDCap)--a metadata-driven methodology and workflow process for providing
740 translational research informatics support. *J Biomed Inform* 42 (2009) 377-81.

- 741 [20] NIH, Common Terminology Criteria for Adverse Events (CTCAE), NIH.
- 742 [21] C.B. Weir, and A. Jan, BMI Classification Percentile And Cut Off Points, StatPearls, Treasure Island
743 (FL), 2023.
- 744 [22] B. Hedblad, P. Nilsson, L. Janzon, and G. Berglund, Relation between insulin resistance and carotid
745 intima-media thickness and stenosis in non-diabetic subjects. Results from a cross-sectional
746 study in Malmo, Sweden. *Diabet Med* 17 (2000) 299-307.
- 747 [23] D.J. Cuthbertson, J. Koskinen, E. Brown, C.G. Magnussen, N. Hutri-Kahonen, M. Sabin, P.
748 Tossavainen, E. Jokinen, T. Laitinen, J. Viikari, O.T. Raitakari, and M. Juonala, Fatty liver index
749 predicts incident risk of prediabetes, type 2 diabetes and non-alcoholic fatty liver disease
750 (NAFLD). *Ann Med* 53 (2021) 1256-1264.
- 751 [24] R.C. Team, R: A language and environment for statistical computing. R Foundation for Statistical
752 Computing, Vienna, Austria, 2022.
- 753 [25] A. Kuznetsova, P.B. Brockhoff, and R.H.B. Christensen, lmerTest Package: Tests in Linear Mixed
754 Effects Models. *Journal of Statistical Software* 82 (2017) 1-26.
- 755 [26] D. Bates, M. Mächler, B. Bolker, and S. Walker, Fitting Linear Mixed-Effects Models Using lme4.
756 *Journal of Statistical Software* 67 (2015) 1–48.
- 757 [27] B. Bolker, D. Robinson, D. Menne, J. Gabry, P. Buerkner, C. Hua, W. Petry, J. Wiley, P. Kennedy, E.
758 Szöcs, I. Patil, V. Arel-Bundock, B. Denney, and C. Brunson, broom.mixed: Tidying Methods for
759 Mixed Models. (2022).
- 760 [28] J.F. Wiley, multilevelTools: Multilevel and Mixed Effects Model Diagnostics and Effect Sizes. (2020).
- 761 [29] M. Koller, robustlmm: An R Package for Robust Estimation of Linear Mixed-Effects Models. *Journal*
762 *of Statistical Software* 75 (2016) 1–24.
- 763 [30] M. Koller, and W.A. Stahel, Robust Estimation of General Linear Mixed Effects Models. *Robust and*
764 *Multivariate Statistical Methods* (2023).
- 765 [31] D. Lüdtke, A. Bartel, C. Schwemmer, C. Powell, A. Djalovski, and J. Titz, sjPlot: Data Visualization for
766 Statistics in Social Science. R package version 2.8.15. (2023).
- 767 [32] S.T. Brookes, E. Whitely, M. Egger, G.D. Smith, P.A. Mulheran, and T.J. Peters, Subgroup analyses in
768 randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction
769 test. *J Clin Epidemiol* 57 (2004) 229-36.
- 770 [33] D.J. O'Keefe, Brief Report: Post Hoc Power, Observed Power, A Priori Power, Retrospective Power,
771 Prospective Power, Achieved Power: Sorting Out Appropriate Uses of Statistical Power Analyses.
772 *Communication Methods and Measures* 1 (2010) 291-299.
- 773 [34] N.L. Bolger, and Jean-Philippe, Intensive longitudinal methods: An introduction to diary and
774 experience sampling research. Guilford Press (2013).
- 775 [35] J. Pinheiro, D. Bates, S. DebRoy, D. Sarkar, S. Heisterkamp, B.V. Willigen, J. Ranke, and R.C. Team,
776 nlme: Linear and Nonlinear Mixed Effects Models. (2023).
- 777 [36] A. Maifeld, H. Bartolomeus, U. Lober, E.G. Avery, N. Steckhan, L. Marko, N. Wilck, I. Hamad, U.
778 Susnjar, A. Mahler, C. Hohmann, C.Y. Chen, H. Cramer, G. Dobos, T.R. Lesker, T. Strowig, R.
779 Dechend, D. Bzdok, M. Kleinewietfeld, A. Michalsen, D.N. Muller, and S.K. Forslund, Fasting
780 alters the gut microbiome reducing blood pressure and body weight in metabolic syndrome
781 patients. *Nat Commun* 12 (2021) 1970.
- 782 [37] C. Laurens, F. Grundler, A. Damiot, I. Chery, A.L. Le Maho, A. Zahariev, Y. Le Maho, A. Bergouignan,
783 G. Gauquelin-Koch, C. Simon, S. Blanc, and F. Wilhelmi de Toledo, Is muscle and protein loss
784 relevant in long-term fasting in healthy men? A prospective trial on physiological adaptations. *J*
785 *Cachexia Sarcopenia Muscle* 12 (2021) 1690-1703.
- 786 [38] J.A. Kraut, and N.E. Madias, Metabolic acidosis: pathophysiology, diagnosis and management. *Nat*
787 *Rev Nephrol* 6 (2010) 274-85.

- 788 [39] Z. Dai, H. Zhang, F. Wu, Y. Chen, C. Yang, H. Wang, X. Sui, Y. Guo, B. Xin, Z. Guo, J. Xiong, B. Wu, and
789 Y. Li, Effects of 10-Day Complete Fasting on Physiological Homeostasis, Nutrition and Health
790 Markers in Male Adults. *Nutrients* 14 (2022).
- 791 [40] C.W. Cheng, G.B. Adams, L. Perin, M. Wei, X. Zhou, B.S. Lam, S. Da Sacco, M. Mirisola, D.I. Quinn,
792 T.B. Dorff, J.J. Kopchick, and V.D. Longo, Prolonged fasting reduces IGF-1/PKA to promote
793 hematopoietic-stem-cell-based regeneration and reverse immunosuppression. *Cell Stem Cell* 14
794 (2014) 810-23.
- 795 [41] E. Oğtodek, and W. Pilis, Is Water-Only Fasting Safe? *Global Advances in Integrative Medicine and*
796 *Health* (2021).
- 797 [42] M. Fanti, A. Mishra, V.D. Longo, and S. Brandhorst, Time-Restricted Eating, Intermittent Fasting, and
798 Fasting-Mimicking Diets in Weight Loss. *Curr Obes Rep* 10 (2021) 70-80.
- 799 [43] C. Pena-Hernandez, K. Nugent, and M. Tuncel, Twenty-Four-Hour Ambulatory Blood Pressure
800 Monitoring. *J Prim Care Community Health* 11 (2020) 2150132720940519.
- 801 [44] E.A. Kaiser, U. Lotze, and H.H. Schäfer, Increasing complexity: which drug class to choose for
802 treatment of hypertension in the elderly? *Clinical Interventions in Aging* 2014 (2014) 459-475.
- 803 [45] E.A. Gebreyohannes, A.S. Bhagavathula, T.B. Abebe, Y.G. Tefera, and T.M. Abegaz, Adverse effects
804 and non-adherence to antihypertensive medications in University of Gondar Comprehensive
805 Specialized Hospital. *Clin Hypertens* 25 (2019) 1.
- 806 [46] LabCorp, Blood Specimens: Chemistry and Hematology.